$CLLS: Cellectis (-20.3%) approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
2
caronte
$CLLS I believe with such good value for money (its target price is 30$+) will be a buying target for astrazeneca (which is already a main shareholder)
1
rlkloehn
$CLLS
The Law Offices of Frank R. Cruz and the office of Howard G. Smith) have announced an investigation into potential infringement of federal securities laws targeting Cellectis S.A. (CLLS)
1
StocktwitsNews
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
$CLLS $ALLO $AZN $IOVA
https://stocktwits.com/news/equity/markets/clls-stock-cellectis-cancer-pivot-citizens-downgrade/cZtneLBRBTz
1
Bigbossmann
$CLLS Not even 1% of the OS shares have traded today, lol. Watch this blow to the moon at EOD!
1
focafoca99
$CLLS has shifted to an in-vivo gene-editing focus, exiting its CAR-T assets and targeting HEAL-101/HEAL-201.
1
rlkloehn
$CLLS today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update
1
Invescent
📉 $CLLS Top Loser #3
Move: down 39.1%
🔴 Financial Health: Weak • 0/100
🔴 Cash Flow Strength: Weak • Free cash flow -$42.50M
🔴 Profitability: Weak • Net margin -92.7%
🟡 Valuation: Not Meaningful • P/E is not meaningful because earnings are negative; P/S is 6.52
Analysis:
Cellectis S. A.
Not financial advice.